Journey101 Home PageArticles

HomeSite MapMail



By Imogen Evans, Hazel Thornton, and Iain Chalmers


1 Silverman WA. Where’s the evidence? Oxford: Oxford University Press, 1998, p165.

2 Tallis R. Enemies of hope: a critique of contemporary pessimism. London: Macmillan,

3 Lock S. Medicine in the second half of the twentieth century. In: Loudon I, ed.
Western medicine: an illustrated history. Oxford: Oxford University Press, 1997.

4 Chalmers I. Unbiased, relevant, and reliable assessments in healthcare. British
Medical Journal 1988;317:1167–8. Citing Bunker JP, Frazier HS, Mosteller F.
Improving health: measuring effects of medical care. Milbank Quarterly,

5 Chalmers I. Evaluating the effects of care during pregnancy and childbirth. In:
Chalmers I, Enkin M, Keirse MJNC, eds. Effective care in pregnancy and childbirth.
Oxford: Oxford University Press, 1989:3–38.

6 Ulfelder H. The stilbestrol disorders in historical perspective. Cancer 1980;45:

7 Office of Technology Assessment. Identifying health technologies that work:
searching for evidence. Washington, DC: US Government Printing Office, 1994.

8 Vandenbroucke JP. Thalidomide: an unanticipated adverse event. Available from: [accessed 5 December 2005].

9 Thomson D, Capstick T. How a risk management programme can ensure safety in
thalidomide use. Pharmaceutical Journal 2004 Feb 14:194–5.

10 Melville A, Johnson C. Cured to death: the effects of prescription drugs. London: New
English Library, 1983.

11 Anonymous. After practolol [Editorial]. British Medical Journal 1977; 17 Dec: 1561–2.

12 Chalmers I. Trying to do more good than harm in policy and practice: the role of
rigorous, transparent, up-to-date evaluations. Annals of the American Academy of
Political and Social Science 2003;589:22–40.

13 Furberg CD. Effect of antiarrhythmic drugs on mortality after myocardial infarction.
American Journal of Cardiology 1983;52:32C–36C.

14 Chalmers I. In the dark. Drug companies should be forced to publish all the results of
clinical trials. How else can we know the truth about their products. New Scientist
2004, 6 Mar, p19. Citing Moore T, Deadly Medicine. New York: Simon and Schuster,

15 Cowley AJ, Skene A, Stainer K, Hampton JR. The effect of lorcainide on
arrhythmias and survival in patients with acute myocardial infarction: an example
of publication bias. International Journal of Cardiology 1993;40:161–6.

16 Horn J, Limburg M. Calcium antagonists for acute ischemic stroke. The Cochrane
Database of Systematic Reviews 2000, Issue 1. Art. No.: CD001928. Available from: [accessed 3 January 2006].

17 Horn J, de Haan RJ, Vermeulen PD, Luiten PGM, Limburg M. Nimodipine in animal
model experiments of focal cerebral ischemia: a systematic review. Stroke

18 Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on
cardiovascular events and cancer: pooled data from clinical trials. British Medical
Journal 1997;315:149–53.

19 Anonymous. HRT: update on the risk of breast cancer and long-term safety.
Current Problems in Pharmacovigilance 2003;29:1–3. Citing results of Women’s
Health Initiative randomised controlled trial (Journal of the American Medical
Association 2003;289:3243–53) and Million Women Study (Lancet 2003;362:

20 Williams HC. Evening primrose oil for atopic dermatitis: time to say goodnight
[Editorial]. British Medical Journal 2003;327:1358–59.

21 Hoare C, Li Wan Po A, Williams H. Systematic review of treatment for atopic
eczema. Health Technology Assessment Report 2000, volume 4, no. 37.

22 Takwale A, Tan E, Agarwal S, et al. Efficacy and tolerability of borage oil in adults
and children with atopic eczema: randomised, double blind, placebo controlled,
parallel group trial. British Medical Journal 2003;327:1385–87.

23 Wilks D, Sissons JGP. Infection. In: Tomlinson S, Heagerty AM, Weetman AP, eds.
Mechanisms of disease: an introduction to clinical science. Cambridge: Cambridge
University Press 1997, pp189–200.

24 Vandenbroucke JP, de Craen AJM. Alternative medicine: a ‘mirror image’ for
scientific reasoning in conventional medicine. Annals of Internal Medicine
2001;135:507–13. Citing Ziegler EJ, Fisher CJ Jr, Sprung CL, et al. Treatment of
gram-negative bacteremia and septic shock with HA-1A human monoclonal
antibody against endotoxin. A randomized, double-blind, placebo-controlled trial.
The HA-1A Sepsis Study Group. New England Journal of Medicine 1991;324:429–36
and citing Bone RC. Immunologic dissonance: a continuing evolution in our
understanding of the systemic inflammatory response syndrome (SIRS) and the
multiple organ dysfunction syndrome (MODS). Annals of Internal Medicine

25 Crile G. A plea against blind fear of cancer. Life, 1955, Oct 31, pp128–32.

26 Baum M, Houghton J. Contribution of randomised controlled trials to
understanding and management of early breast cancer. British Medical Journal

27 Early Breast Cancer Trialists’ Collaborative Group. Effects of adjuvant tamoxifen and
of cytotoxic therapy on mortality in early breast cancer. An overview of 61
randomised trials among 28,896 women. New England Journal of Medicine

28 Kolata G, Eichenwald K. Health business thrives on unproven treatment, leaving
science behind. New York Times Special Report, 1999, Oct 2.

29 Farquhar C, Marjoribanks J, Basser R, et al. High dose chemotherapy and autologous
bone marrow or stem cell transplantation versus conventional chemotherapy for
women with early poor prognosis breast cancer. The Cochrane Database of Systematic
Reviews 2005, Issue 3. Art. No.: CD003139. Available from: [accessed 3 January 2006].

30 Farquhar C, Marjoribanks J, Basser R, et al. High dose chemotherapy and autologous
bone marrow or stem cell transplantation versus conventional chemotherapy for


Designed and Powered by